Noradrenergic versus serotonergic antidepressants: Predictors of treatment response

Journal of Clinical Psychiatry

Volumn 59, Issue SUPPL. 14, 1998, Pages 15-18

  Schatzberg, Alan F ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; ANTIDEPRESSANT AGENT; DESIPRAMINE; NORADRENALIN UPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

CATECHOLAMINE METABOLISM; DEPRESSION; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; HUMAN; PRIORITY JOURNAL; REMISSION; REVIEW; RISK BENEFIT ANALYSIS;

ADRENERGIC UPTAKE INHIBITORS; CATECHOLAMINES; CLINICAL TRIALS; DEPRESSIVE DISORDER; DESIPRAMINE; FLUOXETINE; GTP-BINDING PROTEINS; HUMANS; NOREPINEPHRINE; PROBABILITY; RECEPTOR CROSS-TALK; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 0031663201     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Cookson J. Side-effects of antidepressants. Br J Psychiatry 1993;163: 20-24
2. Stokes PE. Fluoxetine: a five-year review. Clin Ther 1993;15:216-243
3. Anderson IM, Tomenson BM. The efficacy of selective serotonin reuptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol 1990;8:238-249
4. Berzewski H, Van Moffaert M, Gagiano CA. Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive episodes. Eur Neuropsychopharmacol 1997;7:S37-S47
5. Leonard BE. Noradrenaline in basic models of depression. Eur Neuropsychopharmacol 1997;7:S11-S16
6. Schatzberg AF, Orsulak PJ, Rosenbaum AH, et al. Toward a biochemical classification of depressive disorders, V: heterogeneity of unipolar depressions. Am J Psychiatry 1982;139:471-475
7. Maas JW, Fawcett JA, Dekirmenjiam H. Catecholamine metabolism, depressive illness and drug response. Arch Gen Psychiatry 1972;26:252-262
8. Amsterdam JD, Maislin G, Skolnick B, et al. Multiple hormonal responses to clonidine in depressed patients and volunteers. Biol Psychiatry 1989; 26:265-278
9. Potter WZ, Grossman F, Rudoerfer MV. Noradrenergic function in depressive disorders. In: Mann JJ, Kupfer DJ, eds. Biology of Depressive Disorders, Part A: A Systems Perspective. New York, NY: Plenum Press; 1993: 1-27
10. Cheetham SC, Katona CLE, Horton RW. Post-mortem studies of neuro-transmitter biochemistry in depression and suicide. In: Horton R, Katona CLE, eds. Biological Aspects of Affective Disorders. London, England: Academic Press; 1991:192-221
11. Miller HL, Delgado PL, Salomon RM, et al. Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression. Arch Gen Psychiatry 1996;53:117-128
12. Curzon G. Serotonergic mechanisms of depression. Clin Neuropharmacol 1988;11:S11-S20
13. Nordstrom P, Åsberg M. Suicide risk and serotonin. Int Clin Psychopharmacol 1992;6:12-21
14. Schatzberg AF, Rothschild AJ. Serotonin activity in psychotic (delusional) major depression. J Clin Psychiatry 1992;53(10, suppl):52-55
15. Åsberg M, Wagner A. Biochemical effects of antidepressant treatment: studies of monoamine metabolites in cerebrospinal fluid and platelet [3H]imipramine binding. Ciba Found Symp 1986;123:57-83
16. Delgado PL, Charney DS, Price LH, et al. Serotonin function and the mechanism of antidepressant action: reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 1990;47:411-418
17. Smith KA, Fairburn CG, Cowen PJ. Relapse of depression after rapid depletion of tryptophan. Lancet 1997;349:915-919
18. Manji HK. G proteins: implications for psychiatry. Am J Psychiatry 1992; 149:746-760
19. Bowden CL, Schatzberg AF, Rosenbaum A, et al. Fluoxetine and desipramine in major depressive disorder. J Clin Psychopharmacol 1993;13: 305-311
20. Nomura S, Duman RS, Enna SJ. In vivo or in vitro exposure to imipramine reduces alpha 2-adrenoceptor-mediated inhibition of cyclic AMP production in rat brain cerebral cortical slices. Brain Res 1987;410:195-198
21. Nestler EJ, Terwilliger RZ, Duman RS. Chronic antidepressant administration alters the subcellular distribution of cyclic AMP-dependent protein kinase in rat frontal cortex. J Neurochem 1989;53:1644-1647
22. Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 1995;15:7539-7547
23. Nibuya M, Nestler FJ, Duman RS. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 1996;16:2365-2372
24. Mooney JJ, Schatzberg AF, Cole JO, et al. Urinary 3-methoxy-4-hydroxyphenylglycol and the depression-type score as predictors of differential responses to antidepressants. J Clin Psychopharmacol 1991;11: 339-343
25. Schildkraut JJ, Schatzberg AF, Smason JA, et al. Norepinephrine output and metabolism in depressed patients during antidepressant treatments. Clin Neuropharmacol 1992;15(suppl 1, pt A):323A
26. Schatzberg AF, Rosenbaum AH, Bowden CL, et al. Predictors of differential response to fluoxetine and desipramine. Presented at the 35th annual meeting of the American College of Neuropsychopharmacology; December 8-13, 1996; San Juan, Puerto Rico
27. Schatzberg AF, Bowden CL, Rosenbaum AH, et al. Prediction of response to fluoxetine versus desipramine. In: Syllabus and Proceedings Summary of the 145th Annual Meeting of the American Psychiatric Association; May 2-7, 1992; Washington, DC. No. 25D:44
28. Mooney JJ, Schatzberg AF, Cole JO, et al. Rapid antidepressant response to alprazolam in depressed patients with high catecholamine output and heterologous desensitization of platelet adenylate cyclase. Biol Psychiatry 1988; 23:543-559
29. Sharma RP, Janicak PG, Javaid JJ, et al. Platelet MAO inhibition, urinary MHPG and leukocyte beta-adrenergic receptors in depressed patients treated with phenelzine. Am J Psychiatry 1990;147:1318-1321
30. Potter WZ, Scheinin M, Golden RN, et al. Selective antidepressants and cerebrospinal fluid. Arch Gen Psychiatry 1985;42:1171-1177
31. Martensson B, Nyberg S, Torrenson G, et al. Fluoxetine treatment of depression: clinical effects, drug concentrations and monoamine metabolites and N-terminally extended substance P in cerebrospinal fluid. Acta Psychiatr Scand 1989;79:586-596
32. Johnsson MR, Lydiard RB, Morton WA, et al. Effect of fluvoxamine and placebo on catecholamine function in depressed patients. J Psychiatr Res 1993;27:161-172